



Claims

1. A compound represented by general structure (I):




wherein,

- T is a water-soluble vitamin E derivative having a core chromanyl or chromanyl quinone framework and a carboxylic acid moiety substituted at the 2-position, wherein T is connected to nitrogen via the carboxylic acid moiety, as such forming an amide moiety;
- L is a linker between the amide nitrogen atom and the distal nitrogen atom comprising 1 to 10 optionally substituted backbone atoms selected from carbon, nitrogen and oxygen;
- N* is represented by structure (IIa) or (IIb)



- R¹ and R² are each independently selected from hydrogen (H), C₁ – C₆ alkyl or C₁ – C₆ alkenyl, or R¹ and R² are joined together and thus form a second linker between the amide nitrogen atom and the distal nitrogen atom, or R¹ is joined with a backbone atom of the linker L in a cyclic structure and/or R² is joined with a backbone atom of the linker L in a cyclic structure;
 - R³ is selected from hydrogen (H), C₁ – C₆ alkyl or C₁ – C₆ alkenyl, wherein the alkyl or alkenyl moiety may be substituted with one or more halogen atoms, hydroxyl moieties or (halo)alkoxy moieties, or R³ is absent when the distal nitrogen atom is part of an imine moiety; or optionally R³ is joined with a backbone atom of the linker L in a cyclic structure; and
 - R⁴ is selected from hydrogen (H) or C₁ – C₆ alkyl, wherein the alkyl moiety may be substituted with one or more halogen atoms or (halo)alkoxy moieties;
 - X is an anion, preferably a pharmaceutically acceptable anion,
- for use in treating, preventing or suppressing symptoms associated with at least one of:
- a) a mood disorder; and,
 - b) headache and/or migraine.


2. A compound for use according to claim 1, wherein the compound is represented by structure (VI):




(VI)

wherein, N^* is $-NR^3$ or $-N^+R^3R^4 X^-$, wherein T, X, R^3 , and R^4 are as defined in claim 1.

3. A compound for use according to claim 1 or claim 2, wherein T is represented by structure
 5 (IIIa) or (IIIb):



(IIIa)



(IIIb)

wherein R^7 is individually a $C_1 - C_6$ alkyl moiety, preferably each R^7 is methyl.

- 10 4. A compound for use according to any one of claims 1 – 3, wherein the mood disorder comprises depression.
5. A compound for use according to any one of claims 1 – 4, wherein the treatment eliminates, reduces the severity of, and/or reduces the frequency of occurrence of at least one symptom of the
 15 mood disorder, preferably as determined using the Beck Depression Index.
6. A compound for use according to any one of claims 1 – 5, wherein the symptom of the mood disorder includes at least one of apathy, persistent feelings of sadness, feelings of hopelessness or helplessness, having low self-esteem, feeling inadequate, excessive guilt, feelings
 20 of wanting to die, loss of interest in usual activities or activities once enjoyed, difficulty with relationships, sleep disturbances, changes in appetite or weight, decreased energy, difficulty concentrating, a decrease in the ability to make decisions, suicidal thoughts or attempts, frequent physical complaints, running away or threats of running away from home, hypersensitivity to failure or rejection, irritability, hostility, or aggression.
- 25 7. A compound for use according to any one of claims 1 – 6, wherein the treatment further comprises the administration of an additional active agent selected from the group consisting of a norepinephrine reuptake inhibitor, a selective serotonin reuptake inhibitor, a tricyclic antidepressant, a monoamine oxidase inhibitor, and combinations thereof.
- 30 8. A compound for use according to any one of claims 1 – 3, wherein the headache comprises tension-type headaches or wherein the migraine comprises common migraine, classic migraine, familial hemiplegic migraine, sporadic hemiplegic migraine, migraine with brainstem aura, retinal migraine, recurrent migraine and chronic migraine.

9. A compound for use according to any one of claims 1 – 3 and 8, wherein the treatment eliminates, reduces the severity of, and/or reduces the frequency of occurrence of at least one symptom of tension-type headaches or migraine, which symptom preferably includes at least one of (moderate to severe) headaches, and associated symptoms including aura, blurred vision, nausea, vomiting, delirium, nasal stuffiness, diarrhea, tinnitus, polyuria, pallor, sweating, localized edema of the scalp or face, scalp tenderness, prominence of a vein or artery in the temple, stiffness and tenderness of the neck, impairment of concentration and mood, cold and moist feeling in appendages, and sensitivity to light, sound, or smell.
10. A compound for use according to any one of claims 1 – 3 and 8 – 9, wherein the treatment further comprises the administration of an additional active agent selected from the group consisting of a preventive migraine medication, an analgesic, a triptan and an ergotamine.
11. A compound for use according to any one of claims 1 – 10, wherein the total daily dose that is administered is in the range of about 5 to 2000 mg, preferably about 20 to 800 mg, more preferably the total daily dose is in the range of between about 30 to 400 mg and most preferably the total daily dose is in the range of about 150 to 250 mg.
12. A compound for use according to any one of claims 1 – 11, wherein the compound is administered orally, wherein, preferably, the compound is administered in a solid form or in a liquid form, wherein more preferably the compound is admixed with an aqueous solution prior to administration, wherein even more preferably the aqueous solution is an isotonic aqueous solution and wherein most preferably the isotonic aqueous solution is saline.
13. A compound for use according to any one of claims 1 – 12, wherein the compound is administered at least twice daily, preferably wherein the compound is administered twice daily, wherein more preferably the compound is administered twice daily in two similar or equal doses.
14. A compound for use according to claim 13, wherein the interval between two administrations is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.
15. A compound for use according to any one of claims 1 – 14, wherein the subject to be treated is a primate, wherein preferably the subject is a human, wherein preferably the subject to be treated is a patient suffering from a mitochondrial disease.